The global CAR-NK cell therapy market size was valued at USD 346.5 Million in 2025 and is expected to reach USD 1,004.50 Million by 2033,at a CAGR of 14.20% during the forecast period
The market growth is largely fueled by increasing investments in advanced immunotherapies, rising prevalence of cancer, and continuous technological progress in genetic engineering and cell modification techniques, driving wider adoption of CAR-NK cell therapy across clinical and research settings
Furthermore, growing demand for safer and more effective cell-based cancer treatments, along with advantages such as lower risk of graft-versus-host disease and off-the-shelf potential, is accelerating the uptake of CAR-NK cell therapy solutions, thereby significantly boosting the market’s growth
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek